公司概述
Alnylam Pharmaceuticals, Inc. operates as a biotechnology enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutics utilizing ribonucleic acid interference technology across the United States, Europe, and international markets. The company specifically focuses on delivering treatments such as ONPATTRO for hereditary transthyretin-mediated amyloidosis and AMVUTTRA for ATTR and hATTR conditions. This entity functions within the broader healthcare sector, specifically classified under the biotechnology industry, which typically implies high research expenditures and significant potential for regulatory-driven revenue shifts. With a market capitalization of $42.61B and annual revenue reaching $3.71B, the company demonstrates substantial scale supported by an employee base of 2,500. These valuation and revenue figures indicate that Alnylam occupies a leading position within its therapeutic niche, reflecting strong market confidence and established commercialization capabilities despite the inherent risks associated with biotechnology development.
财务健康
The company reported a trailing twelve-month revenue of $3.71B, generating net income of $313.75M and EBITDA of $557.24M. The substantial gap between the $3.71B revenue and the $313.75M net income reveals a cost structure where operating expenses, including research and development, account for a significant portion of gross receipts before reaching the bottom line. However, the business maintains robust operational efficiency, evidenced by a free cash flow of $128.79M, which provides the company with essential financial flexibility to fund future pipeline initiatives without immediate reliance on external capital. Profitability metrics are supported by a gross margin of 81.6%, an operating margin of 12.0%, and a profit margin of 8.4%, each indicating strong pricing power and efficient production scaling. Regarding leverage, the company holds $2.91B in cash against $2.97B in debt, resulting in a debt-to-equity ratio of 376.19, which characterizes a highly leveraged balance sheet typical for growth-stage biotech firms. Despite the high leverage, the current ratio stands at 2.76, indicating a comfortable level of short-term liquidity that allows the firm to meet its obligations. Return on equity is reported at 73.3% while return on assets is 6.8%, suggesting that management is generating high returns on shareholder capital even if asset utilization is moderate relative to the equity base.
估值评估
Valuation multiples show a trailing P/E ratio of 136.71 compared to a forward P/E of 22.62, implying that the market expects a significant expansion in earnings over the coming year that would drastically reduce the multiple. The price-to-book ratio is listed at 53.89, indicating a substantial market premium over the company's tangible book value, which is common for firms with intangible assets like intellectual property. Alternative valuation metrics include a price-to-sales ratio of 11.47 and an EV/EBITDA of 76.57, suggesting that investors are willing to pay a high multiple for sales and earnings given the potential for future growth. In terms of trading range, the stock has a 52-week high of $495.55 and a 52-week low of $205.87, placing the current trading position within a wide band of volatility. The beta value is 0.38, which indicates that the stock's price volatility is significantly lower than that of the broader market, offering a degree of stability relative to large-cap equities.
Growth & Income
Revenue growth is reported at 84.9% year-over-year, while earnings growth is marked as N/A, indicating that earnings are not currently being reported or are not growing at a measurable rate distinct from revenue in the available data. The absence of a dividend yield and a 0.0% payout ratio confirms that the company does not distribute cash to shareholders. Instead, Alnylam reinvests its earnings directly into research, development, and commercialization efforts to expand its therapeutic portfolio. This growth-oriented strategy prioritizes pipeline advancement over income generation for existing investors, which is standard for biotechnology companies in the growth phase. The overall profile reflects a high-growth, non-dividend equity with elevated valuation metrics that rely on future product approvals and market penetration to sustain investor returns.